300 related articles for article (PubMed ID: 20947267)
21. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
Spigel DR; Bendell JC; McCleod M; Shipley DL; Arrowsmith E; Barnes EK; Infante JR; Burris HA; Greco FA; Hainsworth JD
Clin Colorectal Cancer; 2012 Mar; 11(1):45-52. PubMed ID: 21840771
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
[TBL] [Abstract][Full Text] [Related]
24. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
Borg C; André T; Mantion G; Boudghène F; Mornex F; Maingon P; Adenis A; Azria D; Piutti M; Morsli O; Bosset JF
Ann Oncol; 2014 Nov; 25(11):2205-2210. PubMed ID: 25122693
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
26. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Aschele C; Cionini L; Lonardi S; Pinto C; Cordio S; Rosati G; Artale S; Tagliagambe A; Ambrosini G; Rosetti P; Bonetti A; Negru ME; Tronconi MC; Luppi G; Silvano G; Corsi DC; Bochicchio AM; Chiaulon G; Gallo M; Boni L
J Clin Oncol; 2011 Jul; 29(20):2773-80. PubMed ID: 21606427
[TBL] [Abstract][Full Text] [Related]
27. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
Chiarion-Sileni V; Innocente R; Cavina R; Ruol A; Corti L; Pigozzo J; Del Bianco P; Fumagalli U; Santoro A; Ancona E
Cancer Chemother Pharmacol; 2009 May; 63(6):1111-9. PubMed ID: 18825381
[TBL] [Abstract][Full Text] [Related]
28. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
29. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
[TBL] [Abstract][Full Text] [Related]
30. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation.
Calvo FA; Serrano FJ; Diaz-González JA; Gomez-Espi M; Lozano E; Garcia R; de la Mata D; Arranz JA; García-Alfonso P; Pérez-Manga G; Alvarez E
Ann Oncol; 2006 Jul; 17(7):1103-10. PubMed ID: 16670204
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study.
Lee WS; Baek JH; Shin DB; Sym SJ; Kwon KA; Lee KC; Lee SH; Jung DH
Int J Clin Oncol; 2013 Apr; 18(2):260-6. PubMed ID: 22350021
[TBL] [Abstract][Full Text] [Related]
32. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Tezuka T; Hamada C; Ishida H; Ooshiro M; Matsuoka H; Kawasaki S; Mishima H; Maeda K; Sakamoto J; Koda K
Invest New Drugs; 2013 Oct; 31(5):1321-9. PubMed ID: 23817973
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
Wang CC; Liang JT; Tsai CL; Chen YH; Lin YL; Shun CT; Cheng JC
World J Surg Oncol; 2014 Nov; 12():329. PubMed ID: 25373828
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N
J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer.
Koizumi M; Yamada T; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Hara K; Ohta K; Uchida E; Yoshida H
In Vivo; 2018; 32(4):937-943. PubMed ID: 29936483
[TBL] [Abstract][Full Text] [Related]
36. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Peng J; Ren D; Wang J
J Clin Oncol; 2016 Sep; 34(27):3300-7. PubMed ID: 27480145
[TBL] [Abstract][Full Text] [Related]
37. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
38. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Pinto C; Di Fabio F; Maiello E; Pini S; Latiano T; Aschele C; Garufi C; Bochicchio A; Rosati G; Aprile G; Giaquinta S; Torri V; Bardelli A; Gion M; Martoni A
Ann Oncol; 2011 Nov; 22(11):2424-2430. PubMed ID: 21385884
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial.
Koike J; Funahashi K; Yoshimatsu K; Yokomizo H; Kan H; Yamada T; Ishida H; Ishibashi K; Saida Y; Enomoto T; Katsumata K; Hisada M; Hasegawa H; Koda K; Ochiai T; Sakamoto K; Shiokawa H; Ogawa S; Itabashi M; Kameoka S
Cancer Chemother Pharmacol; 2017 Mar; 79(3):519-525. PubMed ID: 28150022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
